Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.55 USD | +1.34% | +0.44% | -26.79% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.79% | 162M | C- | ||
+25.95% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.65% | 352B | C+ | ||
+19.49% | 332B | B- | ||
+3.41% | 283B | C+ | ||
+13.43% | 231B | B+ | ||
+4.71% | 200B | B- | ||
-9.53% | 195B | A+ | ||
-4.47% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SCPH Stock
- Ratings scPharmaceuticals Inc.